Celltrion, Inc. (068270.KS)
KRW 193100.0
(-3.06%)
KRW 193100.0
(-3.06%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2791.73 Billion KRW | 72.6% |
| 2022 | 1617.44 Billion KRW | -0.39% |
| 2021 | 1623.74 Billion KRW | 1.96% |
| 2020 | 1592.54 Billion KRW | 61.4% |
| 2019 | 986.73 Billion KRW | 8.69% |
| 2018 | 907.84 Billion KRW | 2.74% |
| 2017 | 883.59 Billion KRW | 7.37% |
| 2016 | 822.97 Billion KRW | -12.3% |
| 2015 | 938.38 Billion KRW | -3.72% |
| 2014 | 974.6 Billion KRW | 9.34% |
| 2013 | 891.37 Billion KRW | 30.55% |
| 2012 | 682.76 Billion KRW | 34.46% |
| 2011 | 507.76 Billion KRW | 35.2% |
| 2010 | 375.57 Billion KRW | 37.31% |
| 2009 | 273.53 Billion KRW | -2.15% |
| 2008 | 279.54 Billion KRW | 701.67% |
| 2007 | 34.87 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 3145.44 Billion KRW | 12.67% |
| 2024 Q2 | 3133.19 Billion KRW | -0.39% |
| 2023 Q2 | 1895.1 Billion KRW | 2.54% |
| 2023 Q3 | 2075.03 Billion KRW | 9.49% |
| 2023 Q1 | 1848.14 Billion KRW | 14.26% |
| 2023 Q4 | 2791.73 Billion KRW | 34.54% |
| 2023 FY | 2791.73 Billion KRW | 72.6% |
| 2022 Q3 | 1661.55 Billion KRW | 0.7% |
| 2022 Q4 | 1617.44 Billion KRW | -2.65% |
| 2022 Q2 | 1649.97 Billion KRW | -6.1% |
| 2022 FY | 1617.44 Billion KRW | -0.39% |
| 2022 Q1 | 1757.19 Billion KRW | 8.22% |
| 2021 Q3 | 1593.18 Billion KRW | 7.91% |
| 2021 Q4 | 1623.74 Billion KRW | 1.92% |
| 2021 Q1 | 1584.92 Billion KRW | -0.48% |
| 2021 Q2 | 1476.41 Billion KRW | -6.85% |
| 2021 FY | 1623.74 Billion KRW | 1.96% |
| 2020 FY | 1592.54 Billion KRW | 61.4% |
| 2020 Q2 | 1184.28 Billion KRW | 5.8% |
| 2020 Q1 | 1119.38 Billion KRW | 13.44% |
| 2020 Q4 | 1592.54 Billion KRW | 24.05% |
| 2020 Q3 | 1283.79 Billion KRW | 8.4% |
| 2019 Q3 | 981.89 Billion KRW | 4.27% |
| 2019 Q2 | 941.7 Billion KRW | 9.66% |
| 2019 FY | 986.73 Billion KRW | 8.69% |
| 2019 Q1 | 858.74 Billion KRW | -5.41% |
| 2019 Q4 | 986.73 Billion KRW | 0.49% |
| 2018 Q1 | 884.07 Billion KRW | 0.05% |
| 2018 Q4 | 907.84 Billion KRW | 11.12% |
| 2018 Q3 | 816.98 Billion KRW | -2.43% |
| 2018 FY | 907.84 Billion KRW | 2.74% |
| 2018 Q2 | 837.31 Billion KRW | -5.29% |
| 2017 FY | 883.59 Billion KRW | 7.37% |
| 2017 Q2 | 815.74 Billion KRW | -2.69% |
| 2017 Q3 | 826.5 Billion KRW | 1.32% |
| 2017 Q4 | 883.59 Billion KRW | 6.91% |
| 2017 Q1 | 838.27 Billion KRW | 1.86% |
| 2016 Q3 | 795.11 Billion KRW | 0.43% |
| 2016 Q4 | 822.97 Billion KRW | 3.5% |
| 2016 Q1 | 755.35 Billion KRW | -19.51% |
| 2016 FY | 822.97 Billion KRW | -12.3% |
| 2016 Q2 | 791.69 Billion KRW | 4.81% |
| 2015 Q4 | 938.38 Billion KRW | -2.2% |
| 2015 Q3 | 959.48 Billion KRW | 1.33% |
| 2015 FY | 938.38 Billion KRW | -3.72% |
| 2015 Q2 | 946.9 Billion KRW | -10.58% |
| 2015 Q1 | 1058.99 Billion KRW | 8.66% |
| 2014 Q3 | 972.18 Billion KRW | -1.22% |
| 2014 Q2 | 984.16 Billion KRW | 1.07% |
| 2014 FY | 974.6 Billion KRW | 9.34% |
| 2014 Q4 | 974.6 Billion KRW | 0.25% |
| 2014 Q1 | 973.79 Billion KRW | 9.25% |
| 2013 FY | 891.37 Billion KRW | 30.55% |
| 2013 Q4 | 891.37 Billion KRW | -2.47% |
| 2013 Q3 | 913.97 Billion KRW | -0.03% |
| 2013 Q2 | 914.26 Billion KRW | -10.32% |
| 2013 Q1 | 1019.5 Billion KRW | 49.32% |
| 2012 Q4 | 682.76 Billion KRW | 0.0% |
| 2012 Q1 | 556.19 Billion KRW | 0.0% |
| 2012 FY | 682.76 Billion KRW | 34.46% |
| 2011 Q1 | 388.79 Billion KRW | 3.52% |
| 2011 FY | 507.76 Billion KRW | 35.2% |
| 2011 Q3 | 487.97 Billion KRW | 18.82% |
| 2011 Q2 | 410.67 Billion KRW | 5.63% |
| 2010 Q1 | 278.65 Billion KRW | 1.87% |
| 2010 Q4 | 375.57 Billion KRW | 3.2% |
| 2010 FY | 375.57 Billion KRW | 37.31% |
| 2010 Q3 | 363.94 Billion KRW | 12.35% |
| 2010 Q2 | 323.94 Billion KRW | 16.25% |
| 2009 Q3 | 259.09 Billion KRW | -0.6% |
| 2009 Q2 | 260.66 Billion KRW | -13.58% |
| 2009 Q1 | 301.63 Billion KRW | 7.9% |
| 2009 FY | 273.53 Billion KRW | -2.15% |
| 2009 Q4 | 273.53 Billion KRW | 5.57% |
| 2008 Q3 | 307.24 Billion KRW | 1454.77% |
| 2008 Q1 | 26.15 Billion KRW | 0.0% |
| 2008 FY | 279.54 Billion KRW | 701.67% |
| 2008 Q2 | 19.76 Billion KRW | -24.45% |
| 2008 Q4 | 279.54 Billion KRW | -9.01% |
| 2007 Q3 | 23.11 Billion KRW | -0.14% |
| 2007 Q1 | 17.83 Billion KRW | 0.0% |
| 2007 Q2 | 23.15 Billion KRW | 29.78% |
| 2007 FY | 34.87 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ORIENT BIO Inc. | 11.89 Billion KRW | -23376.162% |
| Green Cross Holdings Corporation | 1856.16 Billion KRW | -50.404% |
| Green Cross Holdings Corporation | 1103.45 Billion KRW | -153.001% |
| Pharmicell Co., Ltd. | 18.79 Billion KRW | -14754.153% |
| Green Cross Corporation | 1103.45 Billion KRW | -153.001% |
| GeneOne Life Science, Inc. | 39.51 Billion KRW | -6964.388% |
| Samsung Biologics Co.,Ltd. | 6215.7 Billion KRW | 55.086% |
| SK bioscience Co.,Ltd. | 148.58 Billion KRW | -1778.899% |
| SK Biopharmaceuticals Co., Ltd. | 402.21 Billion KRW | -594.084% |
| Prestige BioPharma Limited | 196.21 Billion KRW | -1322.77% |